Pediatrix Medical Group Reports Third Quarter Results
Pediatrix Medical Group reported Q3 2026 revenue of $501.4 million, up 1.7% year-over-year, with Adjusted EPS of $0.72 versus $0.67 in the prior-year quarter. GAAP net income fell to $47.0 million ($0.59 per diluted share) from $71.7 million ($0.84) a year ago, largely because the prior-year quarter included a $20.9 million gain on divested businesses; Adjusted EBITDA declined to $85.5 million from $87.3 million on higher expenses at existing units. The company spent $83.0 million on share buybacks in the quarter, cutting weighted average shares to 79.7 million from 85.6 million.
Key figures
- Eps
- 0.59
- Revenue
- 501374000
- Guidance
- FY2026 Adjusted EBITDA of $290 million to $300 million
- Revenue Yoy
- 1.7%
- Net income
- 47000000
- Total debt
- 578000000
- Adjusted eps
- 0.72
- Adjusted ebitda
- 85500000
- Cash and equivalents
- 311900000
- Cash from operations
- 117700000
- Share repurchases q3
- 83000000
- Net income prior year
- 71700000
- Adjusted eps prior year
- 0.67
- Adjusted ebitda prior year
- 87300000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.